DLHC Company Profile

Meta Materials Inc declared a jaw-dropping -49.855 %, in Sales, in the financial three months ending December 31 2022

For the most recent fiscal period MMAT decreased a loss per share of $-0.03 per share compare to $-0.22 a year before and earnings per share improved from $-0.07 per share from the preceding reporting period.

Sales faded by -49.855 % to $1.45 millions from $2.88 millions in the comparable reporting period a year before and sequentially Sales Tumbled by -41.135 % from $2.46 millions.

For the financial interval closing December 31 2022 Solid Biosciences Inc decreased a loss per share of $-0.13 per share compare to $-0.16 a year before and EPS improved from $-2.71 per share from the previous financial reporting period.

Sales remained unchanged to $0.00 millions from $3.15 millions in the similar financial reporting period a year before and sequentially Sales Tumbled from $0.00 millions.

The unpleasant -29.802 % fall in Sales at the company all along the most recent fiscal period

For the most recent fiscal period company decreased a loss per share of $-0.32 per share compare to $-0.60 a year before and EPS improved from $-0.42 per share from the preceding reporting season.

Sales crumbled by -29.802 % to $1.24 millions from $1.77 millions in the comparable reporting season a year before and sequentially Sales doubled by 334.737 % from $0.29 millions.

The company reported operating deficit in the fourth quarter of 2022

Trailing the leaders in the Major Pharmaceutical Preparations industry, some overlooked entities are impending with the respective earnings. MGTA said it has reported operating deficit of $-21.732 millions, for the fourth quarter of 2022.

In the financial time-frame ending December 31 2022 company EPS soared by 450.95 % at $0.66 per share, opposite of $0.12 per share a year ago financial reporting period, In the prior financial reporting period Landos Biopharma Inc realized $-0.37 per share.